



Financial Statements  
for the 1<sup>st</sup> quarter of fiscal year ending March 31, 2022  
(From Apr. 1, 2021 to Jun. 30, 2021)

## Summary of consolidated results

**JMS Co., Ltd.**

Company Code No. 7702

August 6, 2021

# Highlights in Business Results



(unit: JPY million)

		Apr. - Jun. 2020 Results	Apr. - Jun. 2021 Results	Diff.	Year-over-Year
Net sales		13,579	13,797	218	1.6%
Operating profit		630	436	(194)	(30.8)%
Ordinary profit		685	478	(207)	(30.3)%
Profit attributable to owners of parent		659	365	(293)	(44.5)%
Basic earnings per share		JPY 27.05	JPY 14.98	---	---
Exchange Rate (average during period)	US Dollar	JPY 107.62	JPY 109.49	<b>Increased in sales (2nd straight year). Decreased in profit.</b>	
	Euro	JPY 120.11	JPY 127.69		
	Singapore Dollar	JPY 76.21	JPY 82.16		


Sales	Recovering trend in refraining from doctor visits and postponing non-essential surgeries and procedures due to the spread of COVID-19.		Profit
	Japan	<ul style="list-style-type: none"> <li>Increased sales of medical glove and Hemodialysis Machines</li> <li>Increased sales of Blood Purification Tubing Sets by transferring of blood purification business</li> </ul>	
	Overseas	<ul style="list-style-type: none"> <li>Decreased sales of Apheresis kits and AV Fistula Needle for North America</li> </ul>	

- Despite the influence of sales increase, the operating profit decreased due to the increase in selling expenses associated with the gradual resumption of sales activities and the increase in R&D expenses
- The addition of share of profit of entities accounted for using equity method resulted in the decrease in ordinary profit

# Summary by segment (geographical area)

(unit: JPY million)


## Japan



**[Sales]** In addition to the increased sales of Medical Gloves and Hemodialysis Machines, increased sales of Blood Purification Tubing Sets by transferring of blood purification business raised net sales.

**[Ordinary Income]** Despite the influence of increased sales, the increase in selling expenses associated with the gradual resumption of sales activities and the increase in R&D expenses resulted in a reduced profit.


## Singapore



**[Sales]** Decreased sales of Apheresis kits and AV Fistula Needle for North America market reduced net sales.

**[Ordinary Income]** Despite the decreased labor costs and selling cost, the influence of decreased sales resulted in a reduced profit.  
\*This segment includes Indonesia local subsidiary.

## China




**[Sales]** Increased sales of AV Fistula Needle and Blood Purification Tubing sets for the Japan market raised net sales.

**[Ordinary Income]** Despite the increase of labor cost, the influence of increase sales resulted in a profit growth.

# Summary by segment (geographical area)

(unit: JPY million)

## Philippines




### [Sales]

Increased sales of Infusion Set for the Japan market raised net sales.

### [Ordinary Income]

The influence of sales increase resulted in the black.

## Germany




### [Sales]

Decreased sales of AV Fistula Needle reduced net sales.

### [Ordinary Income]

The influence of sales decrease resulted in a reduced profit.

## Others




\*This segment includes business activity of subsidiaries in Japan, United States, South Korea and Thailand.


# Sales by Business Segment

Apr. – Jun. 2020


Apr. – Jun. 2021



# Sales change by Region (Customer's Location)




(unit: JPY million)



# Selling, General and Admin. Expenses



(unit: JPY million)




(unit: JPY million)

	Apr. - Jun. 2020	Apr. - Jun. 2021	Diff.	Year-over-Year
Labor Cost	1,446	1,522	76	5.3%
Transport	434	436	2	0.6%
R & D	328	349	21	6.4%
Depreciation	84	91	7	9.1%
Others	853	856	3	0.4%
<b>Total</b>	<b>3,146</b>	<b>3,257</b>	<b>111</b>	<b>3.5%</b>

# Ordinary profit : Compared with the previous year



(unit: JPY million)



# Forecast for FYE Mar. 2022



(unit: JPY million)

	FYE Mar. 2021 Result	FYE Mar. 2022 Forecast	Year-over-Year
Net sales	57,578	58,600	1.8%
Operating profit	2,127	2,100	(1.3)%
Ordinary profit	2,013	2,300	14.2%
Profit attributable to owners of parent	1,736	1,700	(2.1)%
Basic earnings per share	JPY 71.13	JPY 69.61	---

Exchange Rate (average during period)	US Dollar	JPY 106.06	JPY 108
	Euro	JPY 121.81	JPY 128
	(unit: JPY) Singapore Dollar	JPY 77.65	JPY 81

The forecast has been calculated based on the assumption that a certain the impact of COVID-19 will still remain in the subsequent consolidated fiscal years.

-Launched a new 2.5mL type Cell freezing bag "CellQua®".

April. 2021



Cell freezing bag "CellQua®"

-Renewal of our website.

June. 2021



-Notice of the Results of the Initial Assessment of Compliance with the New Market Category (Prime Market)

July. 2021



## The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.